Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Lotus Pharmaceutical Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	6,030	1,771	1,983	1,605	1,489
Cash & Short-Term Investments	6,030	1,771	1,983	1,605	1,489
Cash Growth	240.51%	-10.71%	23.54%	7.82%	16.61%
Accounts Receivable	7,435	6,384	4,651	3,266	2,747
Other Receivables	268.54	233.13	276.24	141.56	53.19
Receivables	7,703	6,617	4,927	3,407	2,801
Inventory	3,833	3,775	3,330	3,073	2,208
Other Current Assets	531.5	489.37	420.4	247.24	284.61
Total Current Assets	18,098	12,653	10,661	8,333	6,783
Property, Plant & Equipment	3,666	3,511	3,148	2,642	2,305
Long-Term Investments	3,594	3,048	2,158	301.73	412.85
Goodwill	6,127	5,670	5,668	5,586	5,896
Other Intangible Assets	5,199	5,487	5,910	2,971	3,177
Long-Term Accounts Receivable	122.73	152.6	-	-	-
Long-Term Deferred Tax Assets	486.42	411.69	390.12	310.82	364.61
Long-Term Deferred Charges	2,639	1,878	1,406	891.98	654.1
Other Long-Term Assets	168.74	180.28	185.33	185.35	161.12
Total Assets	40,101	32,992	29,526	21,222	19,753
Accounts Payable	1,070	670.8	1,403	747.55	1,732
Accrued Expenses	-	3.06	3.57	0.93	2.46
Short-Term Debt	1,615	510	155.92	1,377	410
Current Portion of Long-Term Debt	3,390	1,303	59.95	794.9	1,359
Current Portion of Leases	84.32	70.24	58.99	62.47	40.43
Current Income Taxes Payable	664.47	436.56	731.15	280.16	226.62
Current Unearned Revenue	180.9	132.85	183.08	132.01	132.1
Other Current Liabilities	1,433	1,398	3,297	931.26	980.66
Total Current Liabilities	8,438	4,524	5,893	4,326	4,883
Long-Term Debt	8,384	9,519	8,596	4,667	4,948
Long-Term Leases	194.06	182.2	46.82	43.41	76.58
Long-Term Unearned Revenue	26.56	45.33	65.92	85.96	111.78
Long-Term Deferred Tax Liabilities	1,093	721.2	448.4	304.15	144.69
Other Long-Term Liabilities	112.17	162.29	235.84	224.03	257.46
Total Liabilities	18,921	15,658	15,658	10,153	11,008
Common Stock	2,659	2,650	2,626	2,628	2,454
Additional Paid-In Capital	7,431	7,131	7,534	8,039	6,799
Retained Earnings	12,660	8,900	4,823	1,701	353.66
Treasury Stock	-48.39	-51.1	-57.35	-57.75	-
Comprehensive Income & Other	-1,521	-1,295	-1,058	-1,241	-860.97
Total Common Equity	21,180	17,334	13,868	11,069	8,745
Shareholders' Equity	21,180	17,334	13,868	11,069	8,745
Total Liabilities & Equity	40,101	32,992	29,526	21,222	19,753
Total Debt	13,667	11,585	8,918	6,944	6,834
Net Cash (Debt)	-7,636	-9,814	-6,935	-5,339	-5,345
Net Cash Per Share	-28.99	-37.45	-26.50	-20.80	-21.95
Filing Date Shares Outstanding	265.39	264.47	262.04	262.25	245.35
Total Common Shares Outstanding	265.39	264.47	262.04	262.25	245.35
Working Capital	9,660	8,129	4,768	4,007	1,900
Book Value Per Share	79.81	65.54	52.92	42.21	35.64
Tangible Book Value	9,855	6,177	2,291	2,512	-327.16
Tangible Book Value Per Share	37.13	23.36	8.74	9.58	-1.33
Land	599.33	622.55	622.31	615.49	654.22
Buildings	2,074	1,888	1,384	1,313	1,012
Machinery	1,865	1,826	1,547	1,408	1,324
Construction In Progress	706.38	639.41	1,077	675.22	608.86
Leasehold Improvements	100.15	71.01	87.87	78.26	85.33

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.